Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.
Abstract: Bone marrow-derived mesenchymal stem cells (BM-MSCs) are frequently used in the treatment of musculoskeletal injuries. Fully characterised cells that are readily available for use is optimum. Allogenic BM-MSCs can satisfy the need for rapid treatment, however, their safety has been questioned. Objective: Objectives were to characterise BM-MSCs from an adult donor horse, in vitro, and to identify and describe adverse reactions that occurred following their injection into other horses. We hypothesised that BM-MSCs capable of proliferation, differentiation and lacking MHC II from one donor could be implanted into another individual without significant adverse reactions and the frequency of adverse reactions in clinical cases would be similar to that previously reported for autologous BM-MSCs. Methods: Retrospective clinical study. Methods: BM-MSCs were proliferated and characterised from one donor and cryopreserved for clinical use. Medical records for horses injected with allogenic BM-MSCs from this donor at a single hospital were used. After routine lameness exam, lesions were identified using diagnostic ultrasound or MRI. Post injection reaction was defined as increased pain, swelling, or heat at or near injection site, or increased lameness. Treatments required for each reaction were noted. Results: BM-MSCs proliferated and underwent differentiation. Cells were found to be negative for MHC-II (<2%) and were viable after cryopreservation and shipping. Ten of 230 (4.35%) injections were noted to be associated with an adverse reaction. Adverse reactions occurred in synovial structures (n = 3) and in soft tissues (n = 7). Conclusions: This investigation could underestimate the number and severity of reactions. Mild reactions, such as synovitis, may have been missed. Also, anti-inflammatory drugs could overshadow mild reactions, making them less likely to be detected. Conclusions: Fully characterised allogenic BM-MSCs originating from a single donor horse can be administered to horses with soft tissue injuries with a low rate of adverse reaction. The Summary is available in Portuguese - see Supporting Information.
© 2018 EVJ Ltd.
Publication Date: 2018-08-04 PubMed ID: 29992618DOI: 10.1111/evj.12992Google Scholar: Lookup The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Adverse Effects
- Bone Marrow
- Cell Proliferation
- Cell Viability
- Clinical Study
- Clinical Symptoms
- Cryopreservation
- Disease Treatment
- Equine Health
- Horses
- In Vitro Research
- In Vivo
- Lameness
- Major Histocompatibility Complex (MHC)
- Mesenchymal Cells
- Musculoskeletal System
- Retrospective Study
- Soft Tissue
- Stem Cells
- Veterinary Medicine
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This research article investigates the safety and efficacy of using bone marrow-derived mesenchymal stem cells (BM-MSCs) from a single donor horse for the treatment of musculoskeletal injuries in other horses. The study found that BM-MSCs capable of proliferation and differentiation could be implanted into another individual without significant adverse reactions.
Donor Horse BM-MSC Characterisation and Distribution
- The research centred around characterising BM-MSCs from an adult donor horse in vitro, exploring their abilities to proliferate, differentiate, and their lack of MHC II. These cells were then cryopreserved for clinical use.
- The hypothesis suggested that these cells could be transplanted into recipient horses without causing substantial adverse effects. The frequency of such reactions was also compared to the rates previously reported for autologous BM-MSCs.
Study Methodology
- Researchers used the medical records of horses treated with the allogenic BM-MSCs at a single hospital. After an ordinary lameness examination, the lesions on the horses were identified using diagnostic ultrasound or MRI.
- A reaction post-injection was considered to be an increase in pain, swelling, or heat at or near the injection site, or increased lameness. Any treatments required for these potential reactions were duly noted.
Study Results
- The results demonstrated that these BM-MSCs could proliferate and undergo differentiation, proving viable after cryopreservation and shipping.
- In total, 10 of 230 injections (4.35%) were associated with an adverse reaction; such reactions occurred in synovial structures (n = 3) and soft tissues (n = 7).
Study Limitations and Conclusion
- The researchers admitted that this study might underestimate the number and severity of reactions due to possible overlooking of mild reactions like synovitis. The use of anti-inflammatory drugs could also potentially mask milder reactions.
- In conclusion, the study confirmed that fully characterised allogenic BM-MSCs from a single donor horse could be administered to other horses with a low rate of adverse reactions, demonstrating the potential use of these cells in treating soft tissue injuries.
Cite This Article
APA
Ursini TL, Amelse LL, Elkhenany HA, Odoi A, Carter-Arnold JL, Adair HS, Dhar MS.
(2018).
Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.
Equine Vet J, 51(2), 198-205.
https://doi.org/10.1111/evj.12992 Publication
Researcher Affiliations
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA.
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA.
- Department of Surgery, Faculty of Veterinary Medicine, Alexandria University, Alexandria, Egypt.
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA.
- Oklahoma Equine Hospital, Washington, Oklahoma, USA.
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA.
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA.
MeSH Terms
- Allografts
- Animals
- Bone Marrow Cells
- Horse Diseases / etiology
- Horses
- Injection Site Reaction / veterinary
- Male
- Mesenchymal Stem Cell Transplantation / adverse effects
- Mesenchymal Stem Cell Transplantation / veterinary
- Mesenchymal Stem Cells
Grant Funding
- Tennessee Equine Veterinary Research Organization
Citations
This article has been cited 16 times.- Adamič N, Vengust M. Regenerative medicine in lung diseases: A systematic review. Front Vet Sci 2023;10:1115708.
- Caruso M, Shuttle S, Amelse L, Elkhenany H, Schumacher J, Dhar MS. A pilot study to demonstrate the paracrine effect of equine, adult allogenic mesenchymal stem cells in vitro, with a potential for healing of experimentally-created, equine thoracic wounds in vivo. Front Vet Sci 2022;9:1011905.
- Duddy HR, Schoonover MJ, Hague BA. Outcome following local injection of a liquid amnion allograft for treatment of equine tendonitis or desmitis - 100 cases. BMC Vet Res 2022 Nov 7;18(1):391.
- Bowers K, Amelse L, Bow A, Newby S, MacDonald A, Sun X, Anderson D, Dhar M. Mesenchymal Stem Cell Use in Acute Tendon Injury: In Vitro Tenogenic Potential vs. In Vivo Dose Response. Bioengineering (Basel) 2022 Aug 22;9(8).
- Knott LE, Fonseca-Martinez BA, O'Connor AM, Goodrich LR, McIlwraith CW, Colbath AC. Current use of biologic therapies for musculoskeletal disease: A survey of board-certified equine specialists. Vet Surg 2022 May;51(4):557-567.
- Kamm JL, Riley CB, Parlane NA, Gee EK, McIlwraith CW. Immune response to allogeneic equine mesenchymal stromal cells. Stem Cell Res Ther 2021 Nov 12;12(1):570.
- Nino-Fong R, Esparza Gonzalez BP, Rodriguez-Lecompte JC, Montelpare W, McD￮ L. Development of a biologically immortalized equine stem cell line. Can J Vet Res 2021 Oct;85(4):293-301.
- Aldrich ED, Cui X, Murphy CA, Lim KS, Hooper GJ, McIlwraith CW, Woodfield TBF. Allogeneic mesenchymal stromal cells for cartilage regeneration: A review of in vitro evaluation, clinical experience, and translational opportunities. Stem Cells Transl Med 2021 Nov;10(11):1500-1515.
- Bertoni L, Jacquet-Guibon S, Branly T, Desancé M, Legendre F, Melin M, Rivory P, Hartmann DJ, Schmutz A, Denoix JM, Demoor M, Audigié F, Galéra P. Evaluation of Allogeneic Bone-Marrow-Derived and Umbilical Cord Blood-Derived Mesenchymal Stem Cells to Prevent the Development of Osteoarthritis in An Equine Model. Int J Mol Sci 2021 Mar 2;22(5).
- Voga M, Adamic N, Vengust M, Majdic G. Stem Cells in Veterinary Medicine-Current State and Treatment Options. Front Vet Sci 2020;7:278.
- MacDonald ES, Barrett JG. The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses. Front Vet Sci 2019;6:507.
- Magri C, Schramme M, Febre M, Cauvin E, Labadie F, Saulnier N, François I, Lechartier A, Aebischer D, Moncelet AS, Maddens S. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study. PLoS One 2019;14(8):e0221317.
- Bertoni L, Branly T, Jacquet S, Desancé M, Desquilbet L, Rivory P, Hartmann DJ, Denoix JM, Audigié F, Galéra P, Demoor M. Intra-Articular Injection of 2 Different Dosages of Autologous and Allogeneic Bone Marrow- and Umbilical Cord-Derived Mesenchymal Stem Cells Triggers a Variable Inflammatory Response of the Fetlock Joint on 12 Sound Experimental Horses. Stem Cells Int 2019;2019:9431894.
- Cabon Q, Febre M, Gomez N, Cachon T, Pillard P, Carozzo C, Saulnier N, Robert C, Livet V, Rakic R, Plantier N, Saas P, Maddens S, Viguier E. Long-Term Safety and Efficacy of Single or Repeated Intra-Articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells for Managing Pain and Lameness in Moderate to Severe Canine Osteoarthritis Without Anti-inflammatory Pharmacological Support: Pilot Clinical Study. Front Vet Sci 2019;6:10.
- Rivera Orsini MA, Ozmen EB, Miles A, Newby SD, Springer N, Millis D, Dhar M. Isolation and Characterization of Canine Adipose-Derived Mesenchymal Stromal Cells: Considerations in Translation from Laboratory to Clinic. Animals (Basel) 2024 Oct 15;14(20).
- Quam VG, Belacic ZA, Long S, Rice HC, Dhar MS, Durgam S. Equine bone marrow MSC-derived extracellular vesicles mitigate the inflammatory effects of interleukin-1β on navicular tissues in vitro. Equine Vet J 2025 Jan;57(1):232-242.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
